TransMedics Group (TMDX) Projected to Post Quarterly Earnings on Monday

TransMedics Group (NASDAQ:TMDX) will likely be releasing its earnings data before the market opens on Monday, February 24th. Analysts expect TransMedics Group to post earnings of $0.22 per share and revenue of $109.49 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $72.18 on Monday. The stock has a market capitalization of $2.42 billion, a PE ratio of 76.79 and a beta of 2.12. The business has a 50 day simple moving average of $65.87 and a two-hundred day simple moving average of $106.53. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.37.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of research analyst reports. Robert W. Baird decreased their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Piper Sandler reduced their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $122.70.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.00% of the stock is owned by corporate insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.